Burning Rock Biotech Limited
BNRNASDAQHealthcare● Active
$9.07
$-0.14(-1.52%)
Market Cap$9641782
P/E Ratio—
52W High$41.72
52W Low$2.95
Burning Rock Biotech Limited (BNR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BNR · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 12, 2026EPS Actual
-$0.21
Est. -$1.40 · +85.0%
Revenue
$0.02B
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 12, 2026
After Market Close
▲ Beat EPS🔥 5-Quarter EPS Beat Streak
BNR reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 2, 2026 | -$2.31 | — | — | — | $0.02B | — |
| ◌ Q3 FY2026 | Sep 2, 2026 | -$2.29 | — | — | — | $0.02B | — |
| ▲ Q1 FY2026 | Mar 12, 2026 | -$1.40 | -$0.21 | +85.0% | $0.02B | — | — |
| — Q4 FY2025 | Nov 20, 2025 | — | -$0.26 | — | $0.02B | — | — |
| — Q3 FY2025 | Sep 8, 2025 | — | -$0.15 | — | $0.02B | — | — |
| — Q2 FY2025 | Jun 6, 2025 | — | -$0.17 | — | $0.02B | — | — |
| ▲ Q1 FY2025 | Mar 25, 2025 | -$1.40 | -$1.08 | +22.7% | $0.02B | — | — |
| ▲ Q4 FY2024 | Dec 3, 2024 | -$1.41 | -$0.50 | +64.5% | $0.02B | — | — |
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
-$2.31
EPS Surpr.
—
Revenue
—
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
-$2.29
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
-$0.21
EPS Est.
-$1.40
EPS Surpr.
+85.0%
Revenue
$0.02B
Q4 FY2025
Nov 20, 2025
EPS Actual
-$0.26
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q3 FY2025
Sep 8, 2025
EPS Actual
-$0.15
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q2 FY2025
Jun 6, 2025
EPS Actual
-$0.17
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q1 FY2025
Mar 25, 2025Beat
EPS Actual
-$1.08
EPS Est.
-$1.40
EPS Surpr.
+22.7%
Revenue
$0.02B
Q4 FY2024
Dec 3, 2024Beat
EPS Actual
-$0.50
EPS Est.
-$1.41
EPS Surpr.
+64.5%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $-9.61 | $-9.61 | $-9.61 | 1 |
| Q3 FY2029 | $-9.71 | $-9.71 | $-9.71 | 1 |
| Q2 FY2029 | $-10.22 | $-10.22 | $-10.22 | 1 |
| Q1 FY2029 | $-10.48 | $-10.48 | $-10.48 | 1 |
| Q4 FY2028 | $-12.51 | $-12.51 | $-12.51 | 1 |
| Q3 FY2028 | $-12.44 | $-12.44 | $-12.44 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2029 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2029 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2029 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q3 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 12, 2026 | +85.0% | $23.46 | $22.85 | -2.60% |
| — Q4 FY2025 | Nov 20, 2025 | — | $16.03 | $15.53 | -3.12% |
| — Q3 FY2025 | Sep 8, 2025 | — | $8.30 | $9.06 | +9.16% |
| — Q2 FY2025 | Jun 6, 2025 | — | $2.94 | $2.90 | -1.36% |
| ▲ Q1 FY2025 | Mar 25, 2025 | +22.7% | $5.50 | $4.82 | -12.36% |
| ▲ Q4 FY2024 | Dec 3, 2024 | +64.5% | $6.04 | $6.10 | +0.99% |
| ▲ Q3 FY2024 | Aug 22, 2024 | +90.6% | $6.24 | $6.44 | +3.21% |
| ▲ Q2 FY2024 | May 29, 2024 | +89.5% | $7.55 | $7.55 | +0.00% |
Q1 FY2026-2.60%
Report Date
Mar 12, 2026
EPS Beat/Miss
+85.0%
Price Before
$23.46
Price After
$22.85
Q4 FY2025-3.12%
Report Date
Nov 20, 2025
EPS Beat/Miss
—
Price Before
$16.03
Price After
$15.53
Q3 FY2025+9.16%
Report Date
Sep 8, 2025
EPS Beat/Miss
—
Price Before
$8.30
Price After
$9.06
Q2 FY2025-1.36%
Report Date
Jun 6, 2025
EPS Beat/Miss
—
Price Before
$2.94
Price After
$2.90
Q1 FY2025-12.36%
Report Date
Mar 25, 2025
EPS Beat/Miss
+22.7%
Price Before
$5.50
Price After
$4.82
Q4 FY2024+0.99%
Report Date
Dec 3, 2024
EPS Beat/Miss
+64.5%
Price Before
$6.04
Price After
$6.10
Q3 FY2024+3.21%
Report Date
Aug 22, 2024
EPS Beat/Miss
+90.6%
Price Before
$6.24
Price After
$6.44
Q2 FY2024+0.00%
Report Date
May 29, 2024
EPS Beat/Miss
+89.5%
Price Before
$7.55
Price After
$7.55
Avg Beat Reaction-2.15%
Beat Rate5 / 8 quarters
Largest Move-12.36% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BNR ends December
Burning Rock Biotech Limited (BNR) most recently reported earnings on March 12, 2026 for Q1 FY2026, posting EPS of $-0.21 — beating the analyst consensus of $-1.40 by +85.0%. BNR has beaten EPS estimates for 5 consecutive quarters. The next BNR earnings date is expected around September 1, 2026.
Each quarter, investors track BNR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BNR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BNR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BNR earnings · 5 questionsBurning Rock Biotech Limited's next earnings report is expected around September 1, 2026. BNR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BNR historically reports after market close (AMC).
BNR earnings datewhen is BNR earningsBNR next earnings datewhen does BNR report earningsBNR earnings calendar
▸ Source: FMP · Burning Rock Biotech Limited SEC filings · US GAAP · Burning Rock Biotech Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026